Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 21, 2016; 22(19): 4619-4625
Published online May 21, 2016. doi: 10.3748/wjg.v22.i19.4619
Published online May 21, 2016. doi: 10.3748/wjg.v22.i19.4619
HER2 testing in gastric cancer: An update
Lucas Faria Abrahao-Machado, Cristovam Scapulatempo-Neto, Department of Pathology, Barretos Cancer Hospital, Barretos, SP 14784-400, Brazil
Author contributions: Abrahao-Machado LF performed research, developed and wrote the overall manuscript; and Scapulatempo-Neto C contributed by critically reviewing the manuscript for important intellectual content.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Lucas Faria Abrahao-Machado, MD, Department of Pathology, Barretos Cancer Hospital, Rua Antenor Duarte Villela 1331, Barretos, SP 14784-400, Brazil. lucasfariamachado@yahoo.com
Telephone: +55-17-33216600-6860 Fax: +55-17-33216600-7117
Received: January 19, 2016
Peer-review started: January 21, 2016
First decision: February 18, 2016
Revised: March 2, 2016
Accepted: March 30, 2016
Article in press: March 30, 2016
Published online: May 21, 2016
Peer-review started: January 21, 2016
First decision: February 18, 2016
Revised: March 2, 2016
Accepted: March 30, 2016
Article in press: March 30, 2016
Published online: May 21, 2016
Core Tip
Core tip: It is clear that human epidermal growth factor receptor 2 (HER2) protein over-expression and gene amplification are much more heterogeneous in gastric cancer compared to breast cancer. Gastric and gastroesophageal tumors require a unique immunohistochemistry scoring system and interpretation expertise. We aimed to clarify the key differences in immunohistochemistry interpretation of gastric cancer, providing a practical update on HER2 testing and scoring.